Mitotherapeutix LLC
Woodbridge, US · Founded 2014 · Delaware LLC · 1 known investors
Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity. The company aims to create therapies that treat a range of diseases by controlling this metabolic regulator.
Founders & leadership
Mitotherapeutix LLC was founded in 2014 by Mercedes Rincon.
MR
Mercedes RinconScientific Founder
RH
Robert HemleyCo-Founder & COO
RH
Robert HennesseyCo-Founder & Chairman of Board
JT
Jack TalleyInterim CEO
CA
Cynthia ArbeenyCSO
Board
FE
Fenel EloiBoard director
DW
Daniel WagnerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3M disclosed across 2 rounds · 2016–2017
▶$3MraisedMay 2025 · 5 investors · BiotechnologyRule 506(b)
▶$3MraisedMay 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fenel EloiDirector
- Robert HemleyExecutive Officer, Director
- Robert HennesseyExecutive Officer, Director
- John V. TalleyExecutive Officer, Director
- Daniel WagnerDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Dec 2017
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$30KraisedOct 2016 · 1 investors · BiotechnologyRule 506(b)
▶$30KraisedOct 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert HemleyExecutive Officer, Director
- John TalleyExecutive Officer, Director
- Robert HennesseyExecutive Officer, Director
- Offering amount
- $30K
- Amount sold
- $30K
- First sale
- Sep 2016
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapMitoRx Therapeutics5 shared keywordsMitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
Mitrix4 shared keywordsMitrix Bio develops bioreactor-grown young mitochondria encased in extracellular vesicles ("Mitlets") intended for transplantation to supplement aging cells. The company targets mitochondrial dysfunction implicated in age-related diseases such as Alzheimer's, retinal disease, liver dysfunction, and immune senescence.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Mitotherapeutix LLC for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Mitotherapeutix LLC do?
- Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity. The company aims to create therapies that treat a range of diseases by controlling this metabolic regulator.
- Who founded Mitotherapeutix LLC?
- Mitotherapeutix LLC was founded by Mercedes Rincon in 2014.
- Who are Mitotherapeutix LLC's investors?
- Mitotherapeutix LLC's investors include Connecticut Innovations.
- How much funding has Mitotherapeutix LLC raised?
- Mitotherapeutix LLC has disclosed $3M raised across 2 rounds.
- Where is Mitotherapeutix LLC headquartered?
- Mitotherapeutix LLC is headquartered in Woodbridge, US.